Early-Phase Injectable Formulation Development

Developing robust formulations for injectable therapeutics is a complex process often accompanied by unexpected challenges. Many drug candidates — ranging from small molecules to large biologics — exhibit poor aqueous solubility, particularly at the elevated concentrations required for parenteral delivery. In addition, high viscosity can pose significant hurdles, impacting manufacturability, syringeability, and patient administration. Stability is another critical concern, as many molecules are highly sensitive to environmental stressors such as light, heat, oxidation, and mechanical agitation.

This white paper presents insights from a discussion with three subject matter experts from Thermo Fisher Scientific — Alessandro Chreim, Christy Eatmon, and Liji Joseph — who share their perspectives on overcoming these formulation challenges. Drawing on their experience, the paper outlines practical strategies and industry best practices for developing stable, effective injectable formulations.

Key topics explored include the application of Design of Experiments (DOE) modeling to efficiently optimize formulation parameters, the role of advanced analytical characterization techniques in understanding molecular behavior, and the implementation of risk-based approaches to guide decision-making throughout development. Together, these tools enable a more systematic, data-driven pathway to addressing formulation complexities and accelerating progress toward successful injectable therapies.